HPS2 - THRIVE: Impact of cardiovascular and other adverse events on quality of life and hospital costs
|Dates:||2012 - 2014|
|Funding:||Merck Sharp & Dohme Corp.|
|HERC project team:||Seamus Kent, Boby Mihaylova, Alastair Gray|
|Collaborators:||Clinical Trials Service Unit (CTSU), University of Oxford|
In HPS2-THRIVE 25,673 participants at increased risk of cardiovascular disease were randomised to an extended release niacin/laropiprant combination therapy or matching placebo and followed for an average of 4 years. The main study results, reported in March 2013, indicated that the extended release combination therapy did not reduce the rate of major vascular events (i.e. non-fatal heart attacks, coronary deaths, strokes and revascularisations) and caused a range of side-effects such as skin rashes, gastro-intestinal problems, complications with the management of pre-existing diabetes and increased risk of developing diabetes, infections and gastrointestinal/intracranial bleeding. For more details on HPS2-THRIVE please refer to the study website: http://www.thrivestudy.org/
HERC researchers are collaborating with CTSU to study the impact of cardiovascular and other serious adverse events on health-related quality of life and hospital resource use and costs, using data from this large study. As some of the side effects observed in HPS2-THRIVE occur with other preventative cardiovascular disease interventions (e.g. aspirin, COX-2 inhibitors and statins) the estimates derived using this study data could inform assessments of the net benefits of such interventions taking into account harms as well as benefits.
© 2009 - 2014 University of Oxford